Clinical trial · Interventional
Central Catheters Used for Chemotherapy in Women With Breast Cancer
Evaluation of Central Venous Catheters Used for Chemotherapy in Women With Breast Cancer - An Interdisciplinary Randomized Controlled Study of Complications, Material Wear, Staff- and Patient Perspectives, and Health Economy.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall aim of this study is to evaluate two different central venous lines, PICC-lines (PICC) and subcutaneous venous access ports (SVAP) used for chemotherapy in women with breast cancer. The study will compare complications, material wear of the catheters used, patients'- and health care professionals' experiences, and costs. The study will give knowledge about which central venous access that is the most advantageous regarding adjuvant chemotherapy for women with breast cancer in the aspects of safety, quality of care, and quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Catheter Related Complications | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FEC100 + Taxotere (EC90 + Taxotere) 3+3 | Drug | — | UNRESOLVED |
| FEC75 (or EC90) x 6 | Drug | — | UNRESOLVED |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PICC-Line
- description
- Women allocated to PICC-line when receiving chemotherapy
- interventionNames
- Drug: FEC75 (or EC90) x 6
- Drug: FEC100 + Taxotere (EC90 + Taxotere) 3+3
- Drug: Paclitaxel
- type
- EXPERIMENTAL
- label
- Subcutaneous Venous Access Port (SVAP)
- description
- Women allocated to SVAP when receiving chemotherapy
- interventionNames
- Drug: FEC75 (or EC90) x 6
- Drug: FEC100 + Taxotere (EC90 + Taxotere) 3+3
- Drug: Paclitaxel
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * adjuvant or neo adjuvant chemotherapy, * speak Swedish Exclusion Criteria: * cognitive dysfunction * and/or inability to understand Swedish, * recurrent breast cancer
References
Publications (0)
Data not yet available